Every year, the editors at the Business Observer survey their coverage areas from Tampa to Naples in search of their Entrepreneur of the Year. We are very excited to announce that this year they have selected Steve MacDonald, Founder, Chairman & CEO of myMatrixx. What were they looking for? A great story. Someone who embodies ...Read more

The U.S. Food and Drug Administration (FDA) responded to a petition and decided that the original formulation of Opana ER (oxymorphone hydrochloride) Extended-Release Tablets was not withdrawn from the market for reasons of safety or effectiveness. As a result, generic versions of the original formulation can continue to be approved and marketed. The petition was ...Read more

By Phil Walls, R.Ph, Chief Clinical and Compliance Officer, myMatrixx SB662 passed the senate unanimously on May 1st and will be enacted as law on July 1st pending the governor’s signature. This bill represents a compromise position reached through negotiations between the Florida Medical Association and Automated Healthcare Solutions (AHCS) representing the interests of dispensing ...Read more

The FDA has announced that it will not approve generic versions of the original formulation of OxyContin. OxyContin was first approved by the FDA in December of 1995. The patent on that product expired yesterday. However Purdue Pharma, the manufacturer of OxyContin, ceased distribution of the original formula in August of 2010. In April of ...Read more

On April 15, 2013 the FDA released a reminder regarding the safe storage, use and disposal of fentanyl patches. Fentanyl is a strong pain reliever and the patches are commonly used for treating chronic pain in workers’ compensation patients. The patches are intended to be worn for 3 days (72 hours) each.[1] When the patches ...Read more